Pathogenetic mechanisms of diabetic neuropathy: Lessons from animal models

Journal of the Peripheral Nervous System

Volumn 2, Issue 2, 1997, Pages 113-132

  Yagihashi, Soroku ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Animal models; Axonal atrophy; Cytoskeleton; Diabetic neuropathy; Ischemia; Nerve growth factor; Polyol pathway; Protein glycation; Streptozotocin

Indexed keywords

ANIMAL; DIABETIC NEUROPATHY; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL;

EID: 0031290499     PISSN: 10859489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (197)

1. Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LB: Diabetic neuropathies. Diabetes Care 1992; 15:1926-1975.
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993; 329:977-986.
3. Diabetes Control and Complication Trial (DCCT) Research Group: Effects of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann. Neurol. 1995; 38:869-880.
4. Greene DA, Sima AAF, Albers JW, Pfeifer MA: Diabetic neuropathy. In: Diabetes Mellitus, Theory and Practice (Rifkin H, Porte DP Jr, eds), 4th Ed. New York: Elsevier Sci. Publ. Co., 1990; 710-755.
5. Greene DA, Lattimer SA, Sima AAF: Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N. Engl. J. Med. 1987; 316:599-606.
6. Kennedy L, Baynes JW: Nonenzymatic glycosylation and the chronic complications of diabetes: an overview. Diabetologia 1984; 26:93-988.
7. Sharma AK, Thomas PK: Animal models: Pathology and pathophysiology. In: Diabetic Neuropathy (Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D Jr, eds), Philadelphia: Saunders, 1987; pp. 237-252.
8. Yagihashi S: Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes-Metab. Rev. 1995; 11:193-225.
9. Yagihashi S, Sugimoto K, Wada R: Different neuropathic patterns between type I and type II animal models. In: Pathogenesis and treatment of NIDDM and its related problems (Sakamoto N, Alberti KGMM, Hotta N, eds), Amsterdam: Elsevier, 1994; 401-405.
10. Lukens FDW: Alloxan diabetes. Physiol. Rev. 1948; 28:304-330.
11. Junod A, Lambert AE, Stauffacher W, Renold AE: Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J. Clin. Invest. 1969; 48:2129-2139.
12. Arison RN, Ciaccio EI, Glitzer MS, Cassaro JA, Pruss MP: Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin. Diabetes 1967; 16:51-56.
13. Rakieten N, Gordon BS, Beaty A, Cooney DA, Davis RD, Shein PS: Pancreatic islet cell tumors produced by the combined action of streptozotocin and nicotinamide. Proc. Soc. Exp. Biol. Med. 1971; 137:280-283.
14. Yagihashi S, Nagai K: Immunohistochemical and ultrastructural studies on rat islet cell tumors induced by streptozotocin and nicotinamide. Virchows. Arch. [Pathol. Anat.] 1981; 390:181-191.
15. Greene DA, De Jesus PV, Winegrad AI: Effects of insulin and dietary myo-inositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin-diabetic rats. J. Clin. Invest. 1975; 55:1326-1336.
16. Jakobsen J: Early and preventable changes of peripheral nerve structure and function in insulin-deficient diabetic rats. J. Neurol. Neurosurg. Psychiat. 1979; 42:509-518.
17. Marliss EB, Nakhooda AF, Poussier P, Sima AAF: The diabetic syndrome of the "BB" Wistar rat. Possible relevance to type I (insulin dependent) diabetes in man. Diabetologia. 1982; 22:225-232.
18. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y: Breeding of a non-obese, diabetic strain of mice. Exp. Anim. 1980; 29:1-13.
19. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T: Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41:1422-1428.
20. Goto Y, Kakizaki M, Masaki N: Spontaneous diabetes produced by selective breeding of normal Wistar rats. Proc. Jpn. Acad. 1975; 51:80-85.
21. Robertson DM, Sima AAF: Diabetic neuropathy in the mutant mouse [C57BL/Ks(db/db)]. A morphometric study. Diabetes 1980; 29:60-67.
22. Yagihashi S, Tonosaki A, Yamada K-I, Kakizaki M, Goto Y: Peripheral neuropathy in selectively-inbred spontaneously diabetic rats. Electrophysiological, morphometrical and freeze-replica studies. Tohoku J. Exp. Med. 1982; 138:39-48.
23. Sharma AK, Thomas PK, Gabriel G, Stolinski C, Dockery P, Hollins GW: Peripheral nerve abnormalities in the diabetic mutant mouse. Diabetes 1983; 32: 1152-1161.
24. Suzuki K-I, Hsiao Y-C, Toyota T, Goto Y, Hirata Y, Okada K: The significance of nerve sugar levels for the peripheral nerve impairment of spontaneously diabetic GK (Goto-Kakizaki) rats. Diabetes Res. 1990; 14:21-25.
25. Suzuki KI, Goto Y, Toyota T: Spontaneously diabetic GK (Goto-Kakizaki) rats. In: Lessons from Animal Diabetes IV (Shafrir E, ed), London: Smith Gordon, 1993; 107-116.
26. Kawano K, Hirashima T, Mori S, Natori T: Spontaneously diabetic rat "OLETF" as a model for NIDDM in humans. In: Lessons from Animal Diabetes VI, (Shafrir E, ed.) Boston: Birkhäuser, 1996; 225-236.
27. Hotta N, Koh N, Sakakibara F, Nakamura J, Hamada Y, Hara T, Mori K, Naruse K, Fukasawa H, Kakuta H, Sakamoto N: Nerve function and blood flow in Otsuka Long-Evans Tokushima Fatty rats with sucrose-feeding: Effect of an anti-coagulant. Eur. J. Pharmacol. (in press).
28. Sredy J, Flam BR, Sawicki DR: Adenosine triphosphatase activity in sciatic nerve tissue of streptozocin-induced diabetic rats with and without high dietary sucrose: effect of aldose reductase inhibitors. Proc. Soc. Exp. Biol. Med. 1991; 197:135-143.
29. Cohen AM, Rosenmann Z: Diffuse intercapillary glomerulosclerosis in sucrose-fed rats. Diabetologia 1985; 28:176-180.
30. Hotta N, Kakuta H, Fukasawa H, Kimura M, Koh N, Iida M, Terashima H, Morimura T, Sakamoto N: Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2335, on the development of diabetic neuropathy in streptozotocin-treated rat. Diabetologia 1985; 28:176-180.
31. Gabbay KH, Snider JJ: Nerve conduction defect in galactose-fed rats. Diabetes 1972; 21:295-300.
32. Sharma AK, Thomas PK, Baker RW: Peripheral nerve abnormalities related to galactose administration in rats. J. Neurol. Neurosurg. Psychiatry 1976; 39:794-802.
33. Myers RR, Powell HC: Galactose neuropathy: impact of chronic endoneurial edema on nerve blood flow. Ann. Neurol. 1984; 16:587-594.
34. Powell HC, Myers RR: Schwann cell changes and demyelination in chronic galactose neuropathy. Muscle Nerve 1983; 6:218-227.
35. +-ATPase activity in rats maintained on L-fucose diet. Reversal by myo-inositol supplementation. Diabetes 1993; 42:1401-1406.
36. Ward JD, Barnes CG, Fisher DJ, Jessop JD, Baker RWR: Improvement in nerve conduction following treatment in newly-diagnosed diabetics. Lancet 1971; I:428-431.
37. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M: Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1995; 333:89-94.
38. Ziegler D: Diagnosis, staging and epidemiology of diabetic peripheral neuropathy. Diab. Nutr. Metab. 1994; 7:342-348.
39. Sharma AK, Thomas PK, De Molina AF: Peripheral nerve fiber size in experimental diabetes. Diabetes 1977; 26:689-692.
40. Wright RA, Nukada H: Vascular and metabolic factors in the pathogenesis of experimental diabetic neuropathy in mature rats. Brain 1994; 117:1395-1407.
41. Malone JI, Lowitt S, Korthals JK, Salem A, Miranda C: The effects of hyperglycemia on nerve conduction and structure is age dependent. Diabetes 1996; 45: 209-215.
42. Cameron NE, Cotter MA, Low PA: Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am. J. Physiol. 1991; 261:E1-8.
43. Cameron NE, Cotter MA: The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes-Metab. Rev. 1994; 10:189-224.
44. Greene DA, Lewis RA, Lattimer SA, Brown MJ: Selective effects of myo-inositol administration on sciatic and tibial motor nerve conduction parameters in the streptozotocin-diabetic rat. Diabetes 1982; 31:573-578.
45. Jakobsen J, Lundbaek K: Neuropathy in experimental diabetes: an animal model. Br. Med. J. 1976; 2:278-279.
46. Moore SA, Peterson RG, Felten DL, O'Connor BL: A quantitative comparison of motor and sensory conduction velocities in short- and long-term streptozotocin- and alloxan-diabetic rats. J. Neurol. Sci. 1980; 48:133-152.
47. Thomas PK, Jefferys JGR, Sharma AK, Bajada S: Nerve conduction velocity in experimental diabetes in the rat and rabbit. J. Neurol. Neurosurg. Psychiatry 1981; 4:233-238.
48. Greene DA, Chakrabarti S, Lattimer SA, Sima AAF: Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic Bio-breeding rat. Reversal by insulin replacement, an aldose reductase inhibitor, and myo-inositol. J. Clin. Invest. 1987; 79:1479-1485.
49. Sima AAF, Brismar T, Yagihashi S: Neuropathies encountered in the spontaneously diabetic BB Wistar rat. In: Diabetic Neuropathy (Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D Jr, eds), Philadelphia: Saunders, 1987; 253-259.
50. Yasuda H, Dyck PJ: Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology 1987; 37:20-28.
51. Sima AAF, Nathaniel V, Prashar A, Bril V, Greene DA: Endoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor. Diabetes 1991; 40:1090-1099.
52. Giannini C, Dyck PJ: Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann. Neurol. 1995; 37:498-504.
53. Britland ST, Young RJ, Sharma AK, Clarke BF: Relationship of endoneurial capillary abnormalities to type and severity of diabetic polyneuropathy. Diabetes 1990; 30:909-913.
54. Sugimoto K, Nishida N, Yamagishi SI, Wada RI, Yagihashi S: Structural changes in endoneurial microvessels in rats with chronic streptozotocin-induced diabetes. Morphometric analysis. J. Jpn. Diabetes Soc. 1993; 36:771-778.
55. Uehara K, Sugimoto K, Wada RI, Yoshikawa T, Marukawa K, Yasuda Y, Kimura Y, Yagihashi S: Effects of cilostazol on the peripheral nerve function and structure in STZ-induced diabetic rats. J. Diabetes Compl. (in press).
56. Malik RA, Veves A, Masson EA, Sharma AK, Ah-See AK, Schady W, Lye RH, Boulton AJM: Endoneurial capillary abnormalities in mild human diabetic neuropathy. J. Neurol. Neurosurg. Psychiatry 1992; 55:557-561.
57. Baba M, Wada R, Yagihashi S: Inter-trial variability of the tibial nerve motor nerve conduction in rats. In: Proc. Peripheral Nerve Society, Oct. 6-9, 1995, Antalya, Turkey, 1995; 168.
58. +)-ATPase regulation and diabetic complications. Diabetes 1986; 35:242-245.
59. Greene DA, Lattimer SA: Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozotocin diabetes and its correction by dietary myo-inositol supplementation. J. Clin. Invest. 1983; 72:1058-1063.
60. +)-ATPase regulation in diabetic neuropathy. Ann. N.Y. Acad. Sci. 1986; 488: 334-340.
61. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of complications. N. Engl. J. Med. 1988; 318:1315-1321.
62. Brownlee M: Glycation and diabetic complications. Diabetes 1994; 43:836-841.
63. Low PA: Recent advances in the pathogenesis of diabetic neuropathy. Muscle Nerve 1987; 10:121-128.
64. Low PA, Lagerlund TD, McManis PG: Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic neuropathy. Int. Rev. Neurobiol. 1989; 31: 355-138.
65. Sharma AK, Thomas PK: Peripheral nerve structure and function in experimental diabetes. J. Neurol. Sci. 1974; 23:1-15.
66. Sima AAF, Zhang W-X, Tze WJ, Tai J, Nathaniel V: Diabetic neuropathy in STZ-induced diabetic rat and effect of allogeneic islet cell transplantation. Morphometric analysis. Diabetes 1988; 37:1129-1136.
67. Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ: Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats. Diabetes 1990; 39:690-696.
68. Medori R, Autilio-Gambetti L, Monaco S, Gambetti P: Experimental diabetic neuropathy: Impairment of slow transport with changes in axon cross-sectioned area. Proc. Natl. Acad. Sci. USA 1985; 82:7716-7720.
69. Medori R, Autilio-Gambetti L, Jenich H, Gambetti P: Changes in axon size and slow axonal transport are related in experimental diabetic neuropathy. Neurology 1988; 38:597-601.
70. Yagihashi S, Kamijo M, Watanabe K: Reduced myelinated fiber size correlates with loss of axonal neurofilaments in peripheral nerve of chronically streptozotocin diabetic rats. Am. J. Pathol. 1990; 136:1365-1373.
71. Sharma AK, Bajada S, Thomas PK: Influence of streptozotocin-induced diabetes on myelinated nerve fiber maturation and on body growth in the rat. Acta Neuropathol. 1981; 53:257-265.
72. Sharma AK, Duguid IGM, Blanchard DS, Thomas PK: The effect of insulin treatment on myelinated nerve fibre maturation and integrity and on body growth in streptozotocin-diabetic rats. J. Neurol. Sci. 1985; 67: 285-297.
73. Thomas PK, Fraher JP, O'Leary D, Moran MA, Cole M, King RHM: Relative growth and maturation of axon size and myelin thickness in the tibial nerve of the rat. 2. Effect of streptozotocin-induced diabetes. Acta Neuropathol. 1990; 79:375-386.
74. 1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235. Diabetes 1989; 38:832-838.
75. 1, analogue OP-1206-αCD in streptozocin-induced diabetic rats. Diabetes 1991; 40:726-730.
76. Tamura E, Parry GJ: Severe radicular pathology in rats with longstanding diabetes. J. Neurol. Sci. 1994; 127: 29-35.
77. Brown MJ, Sumner AJ, Greene DA, Diamond SM: Distal neuropathy in experimental diabetes mellitus. Ann. Neurol. 1980; 8:168-178.
78. Zochodne DW, Murray MM, van der Sloot P, Riopelle RJ: Distal tibial mononeuropathy in diabetic and nondiabetic rats reared on wire cages: an experimental entrapment neuropathy. Brain Res. 1995; 698: 130-136.
79. Hoffman PN, Griffin JW, Price DL: Control of axonal caliber by neurofilament transport. J. Cell Biol. 1984; 99:705-714.
80. Friede RL, Samorajski T: Axon caliber relates to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat. Rec. 1970; 167:379-388.
81. Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, Price DW: Neurofilament gene expression: A major determinant of axonal caliber. Proc. Natl. Acad. Sci. USA 1986; 84:3472-3476.
82. Sidenius P, Jakobsen J: Axonal transport in early experimental diabetes. Brain Res. 1979; 173:315-330.
83. Jakobsen J, Sidenius P: Decreased axonal transport of structural proteins in streptozotocin diabetic rats. J. Clin. Invest. 1980; 66:292-297.
84. Sidenius P, Jakobsen J: Reversibility and preventability of the decrease in slow axonal transport velocity in experimental diabetes. Diabetes 1982; 31:689-693.
85. Tomlinson DR, Mayer JH: Reversal of deficits in axonal transport and nerve conduction velocity by treatment of streptozotocin-diabetic rats with myo-inositol. Exp. Neurol. 1985; 89:420-427.
86. Tomlinson DR: The pharmacology of diabetic neuropathy. Diabetes-Metab. Rev. 1992; 8:67-84.
87. Tomlinson DR, Sidenius P, Larsen JR: Slow component-a of axonal transport, nerve myo-inositol, and aldose reductase inhibition in streptozocin-diabetic rats. Diabetes 1986; 35:398-402.
88. Yagihashi S: Axonal cytoskeleton and diabetic neuropathy. Diabetic Med. 1993; 10(Suppl 2):107S-109S.
89. Watanabe K: Molecular biological study on pathogenesis of diabetic neuropathy: alterations in mRN A expression of aldose reductase and axonal cytoskeletal protein. Hirosaki Med. J. 1993; 45:5196-204.
90. Mohiuddin L, Fernyhough P, Tomlinson DR: Reduced levels of mRNA encoding endoskeletal and growth-associated proteins in sensory ganglia in experimental diabetes. Diabetes 1995; 44:25-30.
91. Thomas PK, Wright DW, Tzebelikos E: Amino acid uptake by dorsal root ganglia from streptozotocin-diabetic rats. J. Neurol. Neurosurg. Psychiatry 1984; 47: 912-916.
92. Greene DA, Lattimer SA, Carroll PB, Fernstrom JD, Finegold DN: A defect in sodium-dependent aminoacid uptake in diabetic rabbit peripheral nerve: correction by an aldose reductase inhibitor or myo-inositol administration. J. Clin. Invest. 1990; 85:1657-1665.
93. Bisby MA: Axonal transport of labeled proteins and regeneration rate in nerves of streptozotocin-diabetic rats. Exp. Neurol. 1980; 69:74-84.
94. Longo FM, Powell HC, LeBeau J, Gerrero MR, Heckman BS, Myers RR: Delayed nerve regeneration in streptozotocin diabetic rats. Muscle Nerve 1986; 9: 385-393.
95. Ekström PAR, Tomlinson DR: Impaired nerve regeneration in streptozotocin diabetic rats: effects of treatment with an aldose reductase inhibitor. J. Neurol. Sci. 1989; 93:231-237.
96. Greene LA, Shooter EM: The nerve growth factor: biochemistry, synthesis, and mechanism of action. Annu. Rev. Neurosci. 1980; 3:353-402.
97. Korsching S, Thoenen H: Nerve growth factor in sympathetic ganglia and corresponding target organs of the rat: correlation with density of sympathetic innervation. Proc. Natl. Acad. Sci. USA 1983; 80:3513-3516.
98. Smeyne RJ, Klein R, Schnapp S, Long LK, Bryant S, Lewin A, Lira SA, Barbacid M: Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature 1994; 368: 246-249.
99. Lindsay RM, Harmaer AJ: Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurones. Nature 1989; 37:362-364.
100. Lindsay RM: Nerve growth factors (NGF, BDNF) enhance axonal regeneration but are not required for survival of adult sensory neurons. J. Neurosci. 1988; 8:2394-2405.
101. Verge VMK, Tetzlaff W, Bisby MA, Richardson PM: Influence of nerve growth factor on neurofilament gene expression in mature primary sensory neurons. J. Neurosci. 1990; 10:2018-2025.
102. Brewster NJ, Fernyhough P, Diemel LT, Mohiuddin L, Tomlinson DR: Diabetic neuropathy, nerve growth factor and other neurotrophic factors. Trends Neurosci. 1994; 17:321-325.
103. Hellweg R, Hartung H-D: Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: A possible role for NGF in the pathogenesis of diabetic neuropathy. J. Neurosci. Res. 1990; 26:258-267.
104. Hellweg R, Wöhrle M, Hartung H-D, Stracke H, Hock C, Federlin K: Diabetes mellitus-associated decrease in nerve growth factor levels is reversed by allogeneic pancreatic islet transplantation. Neurosci. Lett. 1991; 125:1-4.
105. Jakobsen J, Brimijoin S, Saku K, Sidenius P, Wells D: Retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in streptozocin-diabetic rats. Diabetes 1981; 30: 797-803.
106. Hellweg R, Raivich G, Hartung H-D, Hoch C, Kreutzberg GW: Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp. Neurol. 1994; 130:24-30.
107. Kasayama S, Oka T: Impaired production of nerve growth factor in the submandibular gland of diabetic mice. Am. J. Physiol. 1989; 257:E400-404.
108. Ordoñez G, Fernandez A, Perez R, Sotelo J: Low contents of nerve growth factor in serum and submaxillary gland of diabetic mice. A possible etiological element of diabetic neuropathy. J. Neurol. Sci. 1994; 121:163-166.
109. Faradji V, Sotelo J: Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol. Scand. 1990; 81:402-406.
110. Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE, Sinicropi DV: The role of endogenous nerve growth factor in human diabetic neuropathy. Nature Med. 1996; 2:703-711.
111. Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA: Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 1994; 634:7-12.
112. Fernyhough P, Diemel LT, Hurdy JH, Brewster WJ, Mohiuddin F, Tomlinson DR: Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat. Eur. J. Neurosci. 1995; 7: 1107-1110.
113. Fernyhough P, Diemel LT, Brewster WJ, Tomlinson DR: Deficits in sciatic nerve neuropeptide content coincide with a reduction in target tissue nerve growth factor messenger RNA in streptozotocin-diabetic rats: effects of insulin treatment. Neuroscience 1994; 62:337-344.
114. Diemel LT, Brewster WJ, Fernyhough P, Tomlinson DR: Expression of neuropeptides in experimental diabetes: effects of treatment with nerve growth factor or brain-derived neurotrophic factor. Mol. Brain Res. 1994; 21:171-175.
115. Whitworth IH, Terenghi G, Green CJ, Brown RA, Stevens E, Tomlinson DR: Targeted delivery of nerve growth factor via fibronectin conduits assists nerve regeneration in control and diabetic rats. Eur. J. Neurosci. 1995; 7:2220-2225.
116. Stevens EJ, Lockett MJ, Carrington AL, Tomlinson DR: Essential fatty acid treatment prevents nerve ischaemia and associated conduction anomalies in rats with experimental diabetes mellitus. Diabetologia 1993; 36:397-401.
117. Williamson JR, Kilo C, Tilton RG: Mechanisms of glucose- and diabetes-induced vascular dysfunction. In: Hyperglycemia, Diabetes, and Vascular Diseases (Ruderman NB, Williamson JR, Brownlee M, eds), New York: Oxford University Press, 1992; 107-132.
118. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, Van den Enden M, Kilo C, Tilton RG: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42:801-813.
119. Ido Y, McHowat J, Chang KC, Arrigoni-Martelli E, Orfalian Z, Kilo C, Corr PB, Williamson JR: Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine. Diabetes 1994; 43:1469-1477.
120. Zochodne DW, Ho LT: Diabetes mellitus prevents capsaicin from inducing hyperaemia in the rat sciatic nerve. Diabetologia 1993; 36:493-496.
121. Zochodne DW, Ho LT: Normal blood flow but lower oxygen tension in diabetes of young rats: Microenvironment and the influence of sympathectomy. Can. J. Physiol. Pharmacol. 1992; 70:651-659.
122. Zochodne DW, Ho LT: The influence of sulindac on experimental streptozotocin-induced diabetic neuropathy. Can. J. Neurol. Sci. 1994; 21:194-202.
123. Nukada H: Increased susceptibility to ischemic damage in streptozocin-diabetic nerve. Diabetes 1986; 35: 1058-1061.
124. Nukada H: Mild ischemia causes severe pathological changes in experimental diabetic nerve. Muscle Nerve 1992; 15:1116-1122.
125. Zochodne DW, Cheng C, Sun H: Diabetes increases sciatic nerve susceptibility to endothelin-induced ischemia. Diabetes 1996; 45:627-632.
126. Zochodne DW, Ho LT, Gross PM: Acute endoneurial ischemia induced by epineurial endothelin in the rat sciatic nerve. Am. J. Physiol. 1992; 263:H1806-H1810.
127. Yagihashi S, Kamijo M, Nagai K: Peripheral neuropathy in diabetic animals: heterogeneous expression of neuropathic patterns in different animal models. In: Frontiers in diabetes research. Lessons from animal diabetes, (Shafrir E, ed), London: Smith-Gordon, 1990, 459-463.
128. Moore SA, Peterson RG, Felten DL, Cartwright TR, O'Conner BL: Reduced sensory and motor nerve conduction velocity in 25-week-old diabetic C57BL/ Ks(db/db) mice. Exp. Neurol. 1980; 70:548-555.
129. Carson KA, Bossen EH, Hanker JS: Peripheral neuropathy in mouse hereditary diabetes mellitus. II. Ultrastructural correlates of degenerative and regenerative changes. Neuropathol. Appl. Neurobiol. 1980; 6:361-374.
130. Sima AAF, Nathaniel V, Bril V, McEwen TAJ, Greene DA: Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J. Clin. Invest. 1988; 81:349-364.
131. Whiteley SJ, Tomlinson DR: Motor nerve conduction velocity and nerve polyols in mice with short-term genetic or streptozotocin-induced diabetes. Exp. Neurol. 1985; 89:314-321.
132. Gillon KRW, Hawthorne JN: Sorbitol, inositol and nerve conduction in diabetes. Life Sci. 1983; 32: 1943-1947.
133. Sharma AK, Thomas PK, Gabriel G, Stolinski C, Deckery P, Hollins GW: Peripheral nerve abnormalities in the diabetic mutant nouse. Diabetes 1983; 32: 1152-1161.
134. Bianchi R, Marelli C, Marini P, Fabris M, Triban C, Fiori MG: Diabetic neuropathy in db/db mice develops independently of changes in ATPase and aldose reductase. A biochemical and immuno-histochemical study. Diabetologia 1990; 33:131-136.
135. Llewelyn JG, Thomas PK, Mirrlees DJ: Aldose reductase activity and myo-inositol levels in sciatic nerve and dorsal root ganglia of the diabetic mutant mouse [C57/BL/KS(db/db)]. Metabolism 1991; 40:1084-1087.
136. +-ATPase activity in galactose-fed mice. Implication for polyol pathway and diabetic neuropathy. Diabetes 1990; 39:663-666.
137. Bagnasco S, Balaban R, Fales HM, Yang Y-M, Burg M: Predominant osmotically active organic solutes in rat and rabbit medulla. J. Biol. Chem. 1986; 261: 5872-5877.
138. Stevens MJ, Lattimer SA, Kamijo M, Van Huysen C, Sima AAF, Greene DA: Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia 1993; 36:608-614.
139. Jeffery JGR, Palmano KP, Sharma AK, Thomas PK: Influence of dietary myo-inositol on nerve conduction and inositol phospholipids in normal and diabetic rats. J. Neurol. Neurosurg. Psychiatry 1978; 41:333-339.
140. +-ATPase activity in isolated membrane fractions from sciatic nerves of streptozocin-induced diabetic rats by dietary myo-inositol supplementation in vivo or protein kinase C agonists in vitro. Diabetes 1991; 40:558-567.
141. Cameron NE, Cotter MA, Dines KC, Maxfield EK: Pharmacological manipulation of vascular endothelium function in non-diabetic and streptozotocin-diabetic rats: effects on nerve conduction, hypoxic resistance and endoneurial capillarization. Diabetologia 1993; 36:516-522.
142. Dyck PJ, Zimmermann BR, Vilen TH, Minnerath SR, Karnes JL, Yao JK, Poduslo JF: Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N. Engl. J. Med. 1988; 319:542-548.
143. Winegrad AI: Does a common mechanism induce the diverse complications of diabetes? Diabetes 1987; 36:396-406.
144. Loy A, Lurie KG, Gosh A, Wilson JM, MacGregor LC, Matschinsky FM: Diabetes and the myo-inositol paradox. Diabetes 1990; 39:1305-1312.
145. King GL, Shiba T, Oliver J, Inoguchi T, Bursell S-E: Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu. Rev. Med. 1994; 45:179-188.
146. Studer RK, Craven PA, DeRobertis FR: Role of protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes 1993; 42:118-126.
147. +-ATPase activity in sciatic nerve of diabetic mice. J. Neurochem. 1992; 58:1246-1249.
148. 2. J. Clin. Invest. 1995; 96:733-740.
149. Lambourne JE, Tomlinson DR, Brown AM, Willars GB: Opposite effects of diabetes and galactosemia on adenosine triphosphatase activity in rat nervous tissue. Diabetologia 1987; 30:360-362.
150. Cotter MA, Cameron NE, Keegan A, Dines KC: Effects of acetyl- and propionyl 1-carnitine on peripheral nerve function and vascular suppy in experimental diabetes. Metabolism 1995; 44:1209-1214.
151. Lowitt S, Malone JI, Salem AF, Korthals J, Benford S: Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 1995; 44:677-680.
152. Yagihashi S, Yamagishi S-I, Wada R, Sugimoto K, Baba M, Wong H-G, Fujimoto J, Nishimura C, Kokai Y: Galactosemic neuropathy in transgenic mice for human aldose reductase. Diabetes 1996; 45:56-59.
153. Yagihashi S, Yamagishi S, Wada R, Aizawa S, Nishimura C, Kokai Y: Enhancement of neuropathic changes in human aldose reductase transgenic mouse rendered diabetic by streptozocin. Diabetes 1994; 43(Suppl 1): 108A.
154. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J. Clin. Invest. 1994; 94:853-859.
155. Lundborg G, Brånemark P-I: Microvascular structure and function of peripheral nerves. Adv. Microcirc. 1968; 1:68-88.
156. Rechtand E, Hervonen A, Sato S, Rapoport SI: Distribution of adrenergic innervation of blood vessels in peripheral nerve. Brain Res. 1986; 374:185-189.
157. Appenzeller O, Dhital KK, Cowen T, Burnstock G: The nerves to blood vessels supplying blood to nerves: the innervation of vasa nervorum. Brain Res. 1984; 304:383-386.
158. Beggs J, Johnson PC, Olafsen A, Watkins CJ, Cleary C: Transperineurial arterioles in human sural nerve. J. Neuropathol. Exp. Neurol. 1991; 50:704-718.
159. Stevens EJ, Tomlinson DR: Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes. Brit. J. Pharmacol. 1995; 115:373-379.
160. Cameron NE, Dines KC, Cotter MA: The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats. Diabetologia 1994; 37:1209-1215.
161. Cerami A, Vlassara H, Brownlee M: Glucose and aging. Sci. Am. 1987; 256:90-96.
162. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation endproducts of proteins. J. Biol. Chem. 1992; 267:14998-15004.
163. Brett J, Schmidt AM, Yan SD, Zou US, Weideman E, Pinsky D, Nowygrod R, Neeper M, Przysieck C, Shaw A, Mighei A, Stern D: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissue. Am. J. Pathol. 1993; 143:1699-1712.
164. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Costache G, Simonescu N, Simonescu M, Stern D: Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulatory AGE proteins. Proc. Natl. Acad. Sci. USA 1994; 91:8807-8811.
165. Vlassara H, Brownlee M, Cerami A: Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc. Natl. Acad. Sci. USA 1981; 78:5190-5192.
166. Williams SK, Howarth NL, Devenny JJ, Bitensky MW: Structural and functional consequences of increased tubulin glycosylation in diabetes mellitus. Proc. Natl. Acad. Sci. USA 1982; 79:6546-6550.
167. Cullum NA, Mahon J, Stringer K, McLean WG: Glycation of rat sciatic nerve tubulin in experimental diabetes mellitus. Diabetologia 1991; 34:387-389.
168. Monnier VM, Kohn RR, Cerami A: Accelerated age-related browning of human collagen in diabetes mellitus. Proc. Natl. Acad. Sci. USA 1984; 81:583-587.
169. Tarsio JF, Wignes B, Rhode TD, Rapp WM, Buchwald H, Furcht LT: Nonenzymatic glycation of fibronectin and alterations in the molecular association of cell matrix and basement membrane components in diabetes mellitus. Diabetes 1985; 34:477-484.
170. Mizisin AP, Powell HC, Myers RR: Edema and increased endoneurial sodium in galactose neuropathy. Reversal with an aldose reductase inhibitor. J. Neurol. Sci. 1986; 74:35-43.
171. Forcier NJ, Mizisin AP, Rimmer MA, Powell HC: Cellular pathology of the nerve microenvironment in galactose intoxication. J. Neuropathol. Exp. Neurol. 1991; 50:235-255.
172. Powell HC, Costello ML, Myers RR: Endoneurial fluid pressure in experimental models of diabetic neuropathy. J. Neuropathol. Exp. Neurol. 1981; 40:613-624.
173. Mizisin AP, Myers RR, Heckman HH, Powell HC: Dose-dependence of endoneurial fluid sodium and chloride accumulation in galactose intoxication. J. Neurol. Sci. 1988; 86:113-124.
174. Williams SK, Solenski NJ: Enhanced vesicular ingestion of nonenzymatically glucosylated proteins by capillary endothelium. Microvasc. Res. 1984; 28:311-321.
175. Patel NJ, Misra VP, Dandona P, Thomas PK: The effect of non-enzymatic glycation of serum proteins on their permeation into peripheral nerve in normal and streptozotocin-diabetic rats. Diabetologia 1991; 34:78-80.
176. Jakobsen J: Peripheral nerve in early experimental diabetes. Expansion of the endoneurial space as a cause of increased water content. Diabetologia 1978; 14: 113-119.
177. Suzuki E, Yasuda K, Yasuda K, Miyazaki S, Takeda N, Inouye H, Omawari N, Miura K: IH-NMR analysis of nerve edema in the streptozotocin-induced diabetic rat. J. Lab. Clin. Med. 1994; 124:627-637.
178. Griffey RH, Eaton RP, Sibbit RR, Sibbitt WL, Bicknell JM: Diabetic neuropathy. Structural analysis of nerve hydration by magnetic resonance spectroscopy. J. Amer. Med. Ass. 1988; 260:2872-2878.
179. Ryle C, Donaghy M: Non-enzymatic glycation of peripheral nerve proteins in experimental diabetes mellitus. In: Proc. Int. Symp. Peripheral Nerve Society, St. Paul, Minnesota, June 12-16, 1994, p.156 (Abstract).
180. Yagihashi S, Sima AAF: Diabetic autonomic neuropathy. The distribution of structural changes in sympathetic nerves of the BB rat. Am. J. Pathol. 1985; 121:138-147.
181. Yagihashi S, Sima AAF: Neuroaxonal and dendritic dystrophy in diabetic autonomic neuropathy. Classification and topographic distribution in the BB-rat. J. Neuropathol. Exp. Neurol. 1986; 45:545-565.
182. Vlassara H, Brownlee M, Cerami A: Excessive nonenzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats. Diabetes 1983; 32:670-674.
183. Federoff HJ, Lawrence D, Brownlee M: Nonenzymatic glycosylation of laminin and the laminin peptide CIKVAVS inhibit neurite outgrowth. Diabetes 1993; 42:509-513.
184. Sugimoto K, Yagihashi S: In situ localization of early and advanced glycation products in the peripheral nerve of STZ-diabetic rats. Diabetes 1995; 44(Suppl 1):32A.
185. Kihara M, Schmelzer JD, Poduslo JF, Curran FF, Nickander KK, Low PA: Aminoguanidine effect on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc. Natl. Acad. Sci. USA 1991; 88:6107-6111.
186. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K: Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992; 41:47-52.
187. Cameron NE, Cotter MA, Dines K, Love A: Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1992; 35:946-950.
188. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JA Jr, Williamson JR, McDaniel ML: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992; 41:552-556.
189. Tilton RG, Chang K, Hasan KS, Smith S, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR: Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end product formation. Diabetes 1993; 42:221-232.
190. Griffiths MJD, Messent M, MacAllister RJ, Evans TW: Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br. J. Pharmacol. 1993; 110:963-968.
191. Sugimoto K, Nishida N, Wada, R: Effects of aminoguanidine on endoneurial vascular abnormalities in experimental diabetic neuropathy. Diabetes 1994; 43(Suppl 1):16A.
192. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK: Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 1994; 37:449-459.
193. Cotter MA, Love A, Watt MJ, Cameron NE, Dines KC: Effects of natural free radical scavengers on periphv eral nerve and neurovascular function in diabetic rats. Diabetologia. 1995; 38:1285-1294.
194. Cameron NE, Cotter MA, Hohman TC: Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Diabetologia 1996; 39: 172-182.
195. Sagara M, Satoh J, Wada R, Yagihashi S, Takahashi K, Fukuzawa M, Muto G, Muto Y, Toyota T: Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia 1996; 39:263-269.
196. Sugimoto K, Yagihashi S: Peripheral nerve pathology in rats with streptozotocin-induced insulinoma. Acta. Neuropathol. 1996; 91:616-623.
197. Pfeifer MA, Schumer MP: Clinical trials of diabetic neuropathy: past, present, and future. Diabetes 1995; 44:1355-1361.